Skip to contentH
HCW Biologics Inc.
H
HCWBHCW Biologics Inc. Q3 2023 · 10-Q
Revenue$853.10K$853.10K−52.8% vs Q3 2022 Net Income-$4.94M-$4.94MN/M vs Q3 2022 EPS Diluted-$0.14-$0.14N/M vs Q3 2022 Gross Profit$174,777−51.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
HCW Biologics Inc. · CIK 1828673 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,589,270N/M Free Cash Flowderived-$6,219,320N/M Margins · derivedGross margin20.5%+0.5 pt vs Q3 2022
Operating margin-595.2%−373.0 pt vs Q3 2022
Net margin-578.9%−362.5 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end